Home › Catalent Biologics And Cerenis Therapeutics Announce Phase III Trial Of CER-001 In Europe And North America Leveraging GPEx Cell Line Technology
 

Keywords :   


Catalent Biologics And Cerenis Therapeutics Announce Phase III Trial Of CER-001 In Europe And North America Leveraging GPEx Cell Line Technology

2016-02-03 03:16:56| drugdiscoveryonline Home Page

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products, today announced that Cerenis Therapeutics has advanced its leading clinical candidate, CER-001, into Phase III clinical studies across Europe and North America

Tags: line technology north iii

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.05Backlash as Morrisons trials sale of New Zealand lamb
16.05LRS Advances Aluminum Can Recovery with EverestLabs Robot, Funded by Can Manufacturers Institute
16.05Paramount selects Vubiquity to provide managed services for MTV Japan
16.05Waste Water Recycling Pilot Coming to Waterloo, Ontario, Canada
16.05New Rules Pending for Reuse And How Movers in This Space Are Doing
16.05Tageos opens RFID manufacturing site in North Carolina
16.05Net Sales Down 10.5% for Grove Collaborative in Q1 2024
16.05Xeikon and Sappi form \'sweet\' partnership
More »